9.32
0.19 (2.08%)
| 前收盘价格 | 9.13 |
| 收盘价格 | 9.00 |
| 成交量 | 60,142 |
| 平均成交量 (3个月) | 72,516 |
| 市值 | 84,313,552 |
| 市盈率 (P/E TTM) | 10.47 |
| 价格/销量 (P/S) | 390.27 |
| 股市价格/股市净资产 (P/B) | 1.91 |
| 52周波幅 | |
| 利润日期 | 12 Mar 2026 |
| 稀释每股收益 (EPS TTM) | -7.95 |
| 总债务/股东权益 (D/E MRQ) | 177.45% |
| 流动比率 (MRQ) | 2.11 |
| 营业现金流 (OCF TTM) | -86.46 M |
| 杠杆自由现金流 (LFCF TTM) | -59.84 M |
| 资产报酬率 (ROA TTM) | -28.22% |
| 股东权益报酬率 (ROE TTM) | -1,556.28% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Seres Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.00 |
|
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 13.01% |
| 机构持股比例 | 35.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Flagship Pioneering, Llc | 31 Dec 2025 | 1,155,850 |
| Lion Point Capital, Lp | 31 Dec 2025 | 31,570 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合